Clinical trial results published by Novartis or in peer-reviewed medical journals

Novartis Buys Private U.S. Radiopharma Firm Mariana Oncology for $1.75B

May 2, 2024, 11:29 AM

Novartis has announced the acquisition of U.S. private radiopharmaceutical company Mariana Oncology for $1 billion, with an additional up to $750 million contingent on milestones. This strategic move aims to strengthen Novartis' position in the radioligand therapy (RLT) space, enhancing its pipeline of drugs targeting cancer cells specifically. The acquisition, backed by investors including Atlas Venture, Access Biotechnology, and RA Capital Management, is part of Novartis' broader strategy to expand its leadership in the radiopharmaceutical field, where it already produces leading drugs.